Renal vasoconstriction to endothelin-1 is enhanced with blockade of endothelin-B receptors or nitric oxide production

D. L. Stacy, R. Martinez, Ronald Tilton

Research output: Contribution to journalArticle

Abstract

Endothelin (ET-1) is a potent renal vasoconstrictor causing an initial transient vasodilation due to activation of ETB receptors and a long-lasting vasoconstriction thought to be due to ETA and ETB receptors. In anesthetized rats ET-1 was infused intravenously {i.V., 1 nmole/kg) after BQ-123 (an ETA receptor antagonist), BQ-788 (an ETB receptor antagonist), or vehicle. Left renal artery flow and mean arterial pressure (MAP) were measured. Resistance was calculated as MAP/flow. ET-1 increased renal resistance by 248% (26±2 to 90±13 mmHg/ml/min.). After pretreatment with BQ-123 (1 mg/kg, i.V.), the increase in renal resistance with ET-1 was reduced by 77% (29±5 to 43±7 mmHg/ml/min.), due to a reduction in the increase in MAP by 81% and decrease in flow by 61%. Pretreatment with BQ-788 (1 mg/kg, i.v.) increased renal resistance after ET-1 markedly (26±3 to 234±89 mmHg/ml/min.). BQ-788 did not alter the presser response to ET-1 but totally blocked the transient vasodilation. Pre-treatment with L-NAME (10 mg/kg i.v.) increased MAP 35 mmHg and reduced renal flow 38%; and after ET-1 renal flow was reduced over 90% for 60 minutes. Thus, the renal pressor effects of ET-1 are primarily mediated through ETA receptors and the vasodilation through ETB receptors in rats. L-NAME does not block the vasodilation with ET-1, so other vasodilators may be involved. There is a considerable amount of constitutive NO released in the rat kidney and ET-1 is much more potent and long-lasting when NO production is blocked.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Endothelin B Receptors
endothelins
vasoconstriction
Endothelin-1
Vasoconstriction
nitric oxide
Nitric Oxide
kidneys
Kidney
Rats
receptors
NG-Nitroarginine Methyl Ester
vasodilation
Vasodilation
Arterial Pressure
Endothelins
Vasoconstrictor Agents
pretreatment
Vasodilator Agents
antagonists

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Renal vasoconstriction to endothelin-1 is enhanced with blockade of endothelin-B receptors or nitric oxide production. / Stacy, D. L.; Martinez, R.; Tilton, Ronald.

In: FASEB Journal, Vol. 10, No. 3, 1996.

Research output: Contribution to journalArticle

@article{b4d946992dbd473c9dedbb1d88bfa8d5,
title = "Renal vasoconstriction to endothelin-1 is enhanced with blockade of endothelin-B receptors or nitric oxide production",
abstract = "Endothelin (ET-1) is a potent renal vasoconstrictor causing an initial transient vasodilation due to activation of ETB receptors and a long-lasting vasoconstriction thought to be due to ETA and ETB receptors. In anesthetized rats ET-1 was infused intravenously {i.V., 1 nmole/kg) after BQ-123 (an ETA receptor antagonist), BQ-788 (an ETB receptor antagonist), or vehicle. Left renal artery flow and mean arterial pressure (MAP) were measured. Resistance was calculated as MAP/flow. ET-1 increased renal resistance by 248{\%} (26±2 to 90±13 mmHg/ml/min.). After pretreatment with BQ-123 (1 mg/kg, i.V.), the increase in renal resistance with ET-1 was reduced by 77{\%} (29±5 to 43±7 mmHg/ml/min.), due to a reduction in the increase in MAP by 81{\%} and decrease in flow by 61{\%}. Pretreatment with BQ-788 (1 mg/kg, i.v.) increased renal resistance after ET-1 markedly (26±3 to 234±89 mmHg/ml/min.). BQ-788 did not alter the presser response to ET-1 but totally blocked the transient vasodilation. Pre-treatment with L-NAME (10 mg/kg i.v.) increased MAP 35 mmHg and reduced renal flow 38{\%}; and after ET-1 renal flow was reduced over 90{\%} for 60 minutes. Thus, the renal pressor effects of ET-1 are primarily mediated through ETA receptors and the vasodilation through ETB receptors in rats. L-NAME does not block the vasodilation with ET-1, so other vasodilators may be involved. There is a considerable amount of constitutive NO released in the rat kidney and ET-1 is much more potent and long-lasting when NO production is blocked.",
author = "Stacy, {D. L.} and R. Martinez and Ronald Tilton",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Renal vasoconstriction to endothelin-1 is enhanced with blockade of endothelin-B receptors or nitric oxide production

AU - Stacy, D. L.

AU - Martinez, R.

AU - Tilton, Ronald

PY - 1996

Y1 - 1996

N2 - Endothelin (ET-1) is a potent renal vasoconstrictor causing an initial transient vasodilation due to activation of ETB receptors and a long-lasting vasoconstriction thought to be due to ETA and ETB receptors. In anesthetized rats ET-1 was infused intravenously {i.V., 1 nmole/kg) after BQ-123 (an ETA receptor antagonist), BQ-788 (an ETB receptor antagonist), or vehicle. Left renal artery flow and mean arterial pressure (MAP) were measured. Resistance was calculated as MAP/flow. ET-1 increased renal resistance by 248% (26±2 to 90±13 mmHg/ml/min.). After pretreatment with BQ-123 (1 mg/kg, i.V.), the increase in renal resistance with ET-1 was reduced by 77% (29±5 to 43±7 mmHg/ml/min.), due to a reduction in the increase in MAP by 81% and decrease in flow by 61%. Pretreatment with BQ-788 (1 mg/kg, i.v.) increased renal resistance after ET-1 markedly (26±3 to 234±89 mmHg/ml/min.). BQ-788 did not alter the presser response to ET-1 but totally blocked the transient vasodilation. Pre-treatment with L-NAME (10 mg/kg i.v.) increased MAP 35 mmHg and reduced renal flow 38%; and after ET-1 renal flow was reduced over 90% for 60 minutes. Thus, the renal pressor effects of ET-1 are primarily mediated through ETA receptors and the vasodilation through ETB receptors in rats. L-NAME does not block the vasodilation with ET-1, so other vasodilators may be involved. There is a considerable amount of constitutive NO released in the rat kidney and ET-1 is much more potent and long-lasting when NO production is blocked.

AB - Endothelin (ET-1) is a potent renal vasoconstrictor causing an initial transient vasodilation due to activation of ETB receptors and a long-lasting vasoconstriction thought to be due to ETA and ETB receptors. In anesthetized rats ET-1 was infused intravenously {i.V., 1 nmole/kg) after BQ-123 (an ETA receptor antagonist), BQ-788 (an ETB receptor antagonist), or vehicle. Left renal artery flow and mean arterial pressure (MAP) were measured. Resistance was calculated as MAP/flow. ET-1 increased renal resistance by 248% (26±2 to 90±13 mmHg/ml/min.). After pretreatment with BQ-123 (1 mg/kg, i.V.), the increase in renal resistance with ET-1 was reduced by 77% (29±5 to 43±7 mmHg/ml/min.), due to a reduction in the increase in MAP by 81% and decrease in flow by 61%. Pretreatment with BQ-788 (1 mg/kg, i.v.) increased renal resistance after ET-1 markedly (26±3 to 234±89 mmHg/ml/min.). BQ-788 did not alter the presser response to ET-1 but totally blocked the transient vasodilation. Pre-treatment with L-NAME (10 mg/kg i.v.) increased MAP 35 mmHg and reduced renal flow 38%; and after ET-1 renal flow was reduced over 90% for 60 minutes. Thus, the renal pressor effects of ET-1 are primarily mediated through ETA receptors and the vasodilation through ETB receptors in rats. L-NAME does not block the vasodilation with ET-1, so other vasodilators may be involved. There is a considerable amount of constitutive NO released in the rat kidney and ET-1 is much more potent and long-lasting when NO production is blocked.

UR - http://www.scopus.com/inward/record.url?scp=33748961644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748961644&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -